Related references
Note: Only part of the references are listed.Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients
Mina Zeinali et al.
CANCERS (2020)
Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
Elaine Kilgour et al.
CANCER CELL (2020)
Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system
Mio Ikeda et al.
CANCER MEDICINE (2020)
Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma
Martha Zavridou et al.
SCIENTIFIC REPORTS (2020)
PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients
Athina Markou et al.
CANCERS (2020)
PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer
Ziyi Sun et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Chien-Hui Weng et al.
ONCOGENE (2019)
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
Zachary A. Yochum et al.
ONCOGENE (2019)
PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway
Lianjing Cao et al.
CANCER LETTERS (2019)
Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer
Jordi Codony-Servat et al.
CLINICAL LUNG CANCER (2019)
EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies
Yijun Jia et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies
Patrycja Pawlikowska et al.
JOURNAL OF THORACIC DISEASE (2019)
PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation
Xuegiang Gao et al.
BREAST CANCER (2019)
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
Donghwa Kim et al.
CELL DEATH & DISEASE (2019)
The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells
Marianna Gallo et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
Luigi Pasini et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Melanie Janning et al.
CANCERS (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients
Areti Strati et al.
CELLS (2019)
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
C. R. Lindsay et al.
EUROPEAN JOURNAL OF CANCER (2019)
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Ping-Chih Hsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Shunli Peng et al.
MOLECULAR CANCER (2019)
Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma
Diego de Miguel-Perez et al.
CANCERS (2019)
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Xuan Zhu et al.
FRONTIERS IN ONCOLOGY (2019)
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Kei Namba et al.
MOLECULAR CANCER RESEARCH (2019)
Current and future perspectives of liquid biopsies in genomics-driven oncology
Ellen Heitzer et al.
NATURE REVIEWS GENETICS (2019)
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer
Anushka Dongre et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy
Menno Tamminga et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Li Jiang et al.
SCIENTIFIC REPORTS (2019)
Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells
Eva Obermayr et al.
ONCOTARGET (2018)
Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC
Tsatsral Iderzorig et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
Galatea Kallergi et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis
Niki Karachaliou et al.
EBIOMEDICINE (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements
G. Kallergi et al.
BREAST CANCER RESEARCH (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?
Cristina Raimondi et al.
ONCOIMMUNOLOGY (2017)
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
Xiao-Ming Jiang et al.
ACTA PHARMACOLOGICA SINICA (2017)
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma
A. Strati et al.
ANNALS OF ONCOLOGY (2017)
AXL-Driven EMT State as a Targetable Conduit in Cancer
Jane Antony et al.
CANCER RESEARCH (2017)
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups
C. R. Lindsay et al.
ANNALS OF ONCOLOGY (2017)
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study
C. J. Morrow et al.
ANNALS OF ONCOLOGY (2016)
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Masahiko Yanagita et al.
CLINICAL CANCER RESEARCH (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
Characterization of different CTC subpopulations in non-small cell lung cancer
Annkathrin Hanssen et al.
SCIENTIFIC REPORTS (2016)
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Chiara Nicolazzo et al.
SCIENTIFIC REPORTS (2016)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches
Matthew G. Krebs et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer
Aliki Stathopoulou et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Share Paper
